Genicular Nerve Block for Pain Management in Patients With Knee Osteoarthritis: A Randomized Placebo‐Controlled Trial
Authors' conclusion
GNB offers short-term pain relief for knee osteoarthritis.
Study context
- Population
- Patients with knee OA and knee paincompleted the trial
- Participants
- 59 patients
- Comparison
- US-guided genicular nerve block vs normal saline injections
- Activen = 31
- Placebon = 28reference
- Primary endpoint
- Pain and disability on a 100-mm visual analog scale (VAS)
- Follow-up
- Weeks 2, 4, 8 and 12
Methodological detailsplacebo-controlled, parallel-group, 12-week, US-guided
- Placebo-controlled
- Parallel-group
- 12-week
- US-guided
Primary result
As reported in the abstract
VAS score, active vs placebo, by time point · baseline and weeks 2, 4, 8, 12
- Baseline: 6.2 vs 5.3
- P = 0.294
- Week 2: 2.7 vs 4.7
- P < 0.001
- Week 4: 3.2 vs 5.1
- P < 0.001
- Week 8: 3.9 vs 4.9
- P < 0.001
- Week 12: 4.6 vs 5.1
- P = 0.055
Further findings
Total WOMAC score, active vs placebo (abstract lists baseline and weeks 2, 4, 6, 8, 12 but prints five value pairs)
- 54.5 vs 48.1
- P = 0.177
- 32.9 vs 44.4
- P < 0.001
- 33.7 vs 45.8
- P < 0.001
- 39.2 vs 44.8
- P = 0.001
- 42.65 vs 45.1
- P = 0.012
Original publication
Genicular Nerve Block for Pain Management in Patients With Knee Osteoarthritis: A Randomized Placebo‐Controlled Trial. Arthritis Rheumatol. Published 11 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →